Thank you for joining our webinar today sponsored by Bayer. Industry Innovations Webinars are archived on the ATS YouTube channel.
Managing adult PAH (WHO Group 1) patients at intermediate
risk. A look at REPLACE: Phase IV Study data.
Please join us for an exciting webinar releasing data from the Phase IV REPLACE (Riociguat rEplacing PDE-5i therapy evaLuated Against Continued PDE-5i thErapy) study.
The REPLACE study was a prospective, randomized, controlled, open label, international, multicenter study evaluating the efficacy of Adempas in adult patients with pulmonary arterial hypertension (PAH) (WHO Group 1) who are receiving a stable dose of a PDE5i and still at intermediate risk.
Adempas is indicated for the treatment of adult patients with PAH to improve exercise capacity, improve WHO Functional Class (FC), and delay clinical worsening.* Efficacy was shown in patients on Adempas monotherapy or in combination with endothelin receptor antagonists (ERA) or prostanoids (PCA). Studies establishing effectiveness included predominantly patients with WHO FC II–III.
* Time to clinical worsening was a combined endpoint defined as death (all-cause mortality), heart/lung transplantation, atrial septostomy, hospitalization due to persistent worsening of pulmonary hypertension, start of a new PAH-specific treatment, persistent decrease in 6MWD, and persistent worsening of WHO functional class.
This program is sponsored by Bayer.
By registering for this webinar, you agree your information will be shared with the sponsor.
No CME or MOC credits are available for this program.
Opinions expressed and resources shared may not have been reviewed by the ATS prior to distribution through ATS channels, or reflect official positions of the ATS, unless it is explicitly noted as a result of official ATS approval. References to specific commercial entities (companies) or products do not reflect review or endorsement by the ATS unless it is explicitly noted as a result of official ATS approval.